Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Patients requiring a permanent pacemaker after TAVR face higher long-term risk of death
As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.
CMS proposes Medicare coverage for T-TEER
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.

AI can help cardiologists predict death after TAVR—but there is a catch

It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis.

The waiting game: Delaying TAVR increases healthcare costs by $10K per year

Delaying TAVR in eligible patients with severe AS can lead to much higher healthcare costs, according to a new study of real-world Medicare data.

doctor patient discharge after heart surgery

TAVR vs. SAVR for low-risk patients: Cardiologist explores the decision-making process

While multiple studies have confirmed that TAVR and surgery are associated with comparable outcomes, it is important to take an individualized approach to all treatment decisions.

The Tria surgical mitral valve is built using LifePolymer, a proprietary material that does not include animal tissue. Both the frame of the valve and its leaflets are generated by computer to match each patient’s native mitral valve. According to Foldax, this new-look polymer reduces the long-term risk of valve calcification, and patients should be able to bounce back after surgery without requiring the long-time use of anticoagulants.

New-look polymer mitral valve linked to positive outcomes 30 days after surgery

The new surgical valve from Foldax was designed to limit calcification and make it so patients do not require long-term anticoagulant therapy following treatment.

Medtronic TAVR valves at heart of multiple sessions during New York cardiology conference

Medtronic’s TAVR technology received a significant amount of attention during the very first New York Valves conference in New York City. Research focused on patients with small annuli as well as how five-year outcomes compare to surgery.

Edwards shares new data highlighting consistency of its TAVR valves in women, patients with small annuli

Researchers explored five-year data from more than 1,300 TAVR patients treated with a balloon-expandable Sapien 3 valve, sharing their findings at New York Valves 2024: The Structural Heart Summit.

The rapid rise of artificial intelligence (AI) has helped cardiologists, radiologists, nurses and other healthcare providers embrace precision medicine in a way that ensures more heart patients are receiving personalized care.

AI uses imaging results to ID high-risk TAVR patients with speed, accuracy

Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value.

Structural Heart Disease

Patients requiring a permanent pacemaker after TAVR face higher long-term risk of death

CMS proposes Medicare coverage for T-TEER

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure